Mandrake Bio Raises $1.9M Pre-Seed for AI-Native Protein Design

Mandrake Bio, a Bengaluru-based biotechnology startup, has raised approximately $1.9M in pre-seed funding. The round was co-led by Activate and Antler, with participation from Spectrum Impact, DeVC, and strategic angel investors including Dr. Vijay Chandru, Paras Chopra, Sanjiv Rangrass, and Vatsal Dusad.

The company is building AI-native protein design infrastructure that creates programmable gene-editing enzymes from scratch rather than adapting naturally occurring systems such as CRISPR-Cas9. The capital will support expansion of Mandrake Bio's AI research platform, compute infrastructure, AI and biophysics hiring, and wet-lab validation of engineered proteins.

For operators and investors, the signal extends beyond one pre-seed biotechnology company. AI's most valuable applications are moving beyond software interfaces and into scientific infrastructure, where breakthroughs are measured by validated systems rather than weekly product launches.

What Happened

Mandrake Bio secured approximately $1.9M, or Rs 16 crore, in pre-seed funding to expand its AI-native protein design platform. The round was co-led by Activate and Antler, with additional participation from Spectrum Impact, DeVC, and angel investors Dr. Vijay Chandru, Paras Chopra, Sanjiv Rangrass, and Vatsal Dusad.

Founded in Bengaluru, Mandrake Bio is developing programmable gene-editing enzymes through AI-driven protein design. Rather than modifying existing biological systems, the company focuses on designing new enzymes using generative AI, structural biology, biophysics, and iterative laboratory validation.

Mandrake Bio's team is led by founder Tanay Lohia, whom the company identifies as Founder and Chief Editing Officer, alongside Dr. Kutubuddin Molla, Chief Scientific Advisor. The company's work combines computational biology with experimental science to build foundational infrastructure for programmable biology.

Why This Matters

Every technology cycle has its fashionable layer, and right now that layer is conversational AI. History often rewards the companies building beneath the headlines, which is why Mandrake Bio's infrastructure thesis is more interesting than a typical funding round.

Instead of treating AI as another productivity feature, Mandrake Bio is applying machine learning to one of biology's more difficult engineering problems: designing functional proteins from first principles. Traditional gene-editing approaches typically build on naturally occurring biological systems, while Mandrake Bio's approach is to generate programmable enzymes de novo and expand the possible design space.

If that works, the conversation shifts from discovering biology to engineering biology. That is not simply a scientific milestone. It is an infrastructure play for agriculture, therapeutics, and any market where programmable biological tools could become a foundational platform.

Market Context

Artificial intelligence is becoming foundational across scientific disciplines. Biology is one of the most promising intersections because advances in machine learning are improving how researchers model protein structures, predict biological interactions, and accelerate experimental cycles.

Mandrake Bio sits directly within that convergence. Its initial commercial focus is agriculture, where more compact and programmable gene-editing tools could support crop improvement, pest resilience, climate adaptation, and reduced agricultural inputs.

The company's longer-term vision also includes therapeutic applications, where programmable gene-editing technologies continue to attract significant global research investment. Rather than moving directly into end-user applications, Mandrake Bio is positioning itself as an infrastructure company whose engineered enzymes could eventually be licensed to seed companies and therapeutic developers.

Competitive Landscape

The biotechnology industry has seen enormous investment in gene editing over the past decade, with CRISPR becoming synonymous with the category. Mandrake Bio is pursuing a different technical philosophy by developing programmable gene-editing enzymes designed from scratch through AI-native protein design.

The company describes an approach that combines generative AI, structural biology, biophysics, and continuous wet-lab validation to iteratively improve engineered proteins. That strategy is more challenging than incremental optimization, but it creates the possibility of biological tools tailored to specific use cases rather than constrained by inherited limitations.

This is why early-stage investors such as Activate and Antler are paying attention. Deep technical differentiation is often established long before commercial scale arrives, and the companies that own foundational capabilities can become difficult to displace once the market catches up.

What This Signals

The funding environment continues to reward ambitious technical companies solving foundational problems instead of chasing short-term software trends. Mandrake Bio raised institutional capital before commercial maturity because investors are underwriting technical capability, research depth, and long-term infrastructure potential rather than immediate revenue.

That signals an important shift across venture capital. Increasingly, compelling AI investments are emerging where machine learning intersects with biology, chemistry, materials science, and advanced engineering, even when those companies do not resemble traditional software startups.

For founders, the lesson is straightforward. Sophisticated investors remain willing to fund difficult science when the technical thesis is coherent, the execution strategy is credible, and the market opportunity extends beyond a single product.

The Bigger Industry Shift

Artificial intelligence is becoming less about replacing knowledge work and more about expanding what humanity can build. Protein design is one example. Materials discovery, advanced manufacturing, and scientific computing are others.

Mandrake Bio reflects a broader movement toward AI-native scientific infrastructure: platforms that combine computation with experimentation to create capabilities that were previously impractical or impossible. That evolution may ultimately prove more economically significant than another generation of productivity software.

The companies defining this era will look different from the software giants that dominated the previous one. They will operate laboratories alongside compute clusters, employ biologists alongside machine-learning researchers, and measure progress through validated experiments as much as product releases.

Mandrake Bio's pre-seed financing is still an early chapter. But it illustrates where sophisticated capital is increasingly looking: toward companies building foundational technologies capable of reshaping entire industries over the long term.